HTLF Bank Buys New Holdings in Amgen Inc. (NASDAQ:AMGN)

HTLF Bank bought a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 30,452 shares of the medical research company's stock, valued at approximately $8,771,000. Amgen comprises approximately 1.0% of HTLF Bank's investment portfolio, making the stock its 21st biggest position.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Roundview Capital LLC increased its position in Amgen by 1.3% in the 1st quarter. Roundview Capital LLC now owns 8,383 shares of the medical research company's stock worth $2,027,000 after buying an additional 107 shares during the period. Merit Financial Group LLC increased its position in Amgen by 39.2% in the 1st quarter. Merit Financial Group LLC now owns 2,297 shares of the medical research company's stock worth $555,000 after buying an additional 647 shares during the period. Ergoteles LLC bought a new position in Amgen in the 1st quarter worth approximately $219,000. First Western Trust Bank bought a new position in Amgen in the 1st quarter worth approximately $334,000. Finally, Fuller & Thaler Asset Management Inc. increased its position in Amgen by 2.1% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 24,688 shares of the medical research company's stock worth $5,970,000 after buying an additional 513 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Price Performance

Amgen stock traded up $6.18 on Friday, reaching $268.93. The company's stock had a trading volume of 3,380,202 shares, compared to its average volume of 2,858,917. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The company has a market cap of $144.12 billion, a price-to-earnings ratio of 21.53, a PEG ratio of 2.46 and a beta of 0.58. The business's fifty day moving average price is $276.90 and its 200 day moving average price is $281.26. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping analysts' consensus estimates of $4.66 by $0.05. The company had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The business's revenue was up 19.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.09 earnings per share. Equities analysts expect that Amgen Inc. will post 19.45 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 3.35%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen's dividend payout ratio (DPR) is presently 72.06%.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. TD Cowen dropped their price target on Amgen from $370.00 to $360.00 and set a "buy" rating on the stock in a research report on Wednesday. UBS Group lowered their price objective on Amgen from $314.00 to $284.00 and set a "neutral" rating on the stock in a research report on Wednesday. Oppenheimer restated an "outperform" rating and set a $350.00 price objective on shares of Amgen in a research report on Thursday, February 1st. Truist Financial restated a "buy" rating and set a $320.00 price objective on shares of Amgen in a research report on Friday, April 12th. Finally, StockNews.com cut Amgen from a "buy" rating to a "hold" rating in a research report on Thursday, March 28th. Ten research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $296.95.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.